Clinical Trial Search

Primary: Number of Participants With Adequate Exposure and Access to Oropharyngeal and Hypopharyngeal Head and Neck Lesions — 147; 23 participants

Primary: Total Surgical Time, All Resident Levels — 58.0; 54.0 minutes — p=0.053

Primary: Change From Baseline in Left Ventricular Mass Index (LVMI) — -6.071; -4.008 g/m^2.7

Primary: Progression Free Survival With Sunitinib as First Line of Therapy — 18.4 months

Primary: Percentage of Participants With Sustained Virologic Response (SVR) at 12 Weeks After Discontinuation of Therapy (SVR12) — 89.5; 84.8; 84.0; 90.9 percentage of participants

Primary: Corneal Swelling — 569.42; 574.64; 575.57; 578.99 microns

Primary: Profile of Mood Scale Total Negative Affect (Tension + Depression + Anger) — 8.52; 8.096; 5.14; 4.615 units on a scale

Primary: Sensitivity for R Waves During In-Clinic Recordings at Rest — 100 percentage of recordings

Primary: Change Score in the Self-assessment of Disability as Measured by Oswestry Disability Index (ODI) — 2.4; 8.1; 14.0 units on a scale — p=.01

Primary: Mean Change From Baseline BCVA — 14; 5 Letters (ETDRS chart)

Primary: Treatment Engagement — 4.2; 1.4; 7.2; 1.5 number of treatment sessions attended — p=<0.001

Primary: Change From Baseline to Visit 2 in the Sum Score Calculated From the 4 Items of the Affective Dimension of the Pain Description List (Schmerzbeschreibungsliste SBL…

Primary: Rate of Subjects With PRNT50 Titers of ≥ 1:10 at Month 12 After the First IC51 Vaccination (in Study IC51-322) — 89.5 percentage of participants

Primary: Is Chronic Opioid Treatment Associated With Changes in Adrenocorticotropic Hormone (ACTH), Cortisol, Luteinizing Hormone (LH) and Testosterone Secretion? — NA; NA ng/ml

Primary: Proportion of Patients With Complete TMA Response — 63.6 Percentage of Participants